CAJ | 학술논문

支气管哮喘(简称哮喘)是由多种因素引起的疾病,目前公认的发病机制是气道炎症假说.近来研究表明,胰岛素受体底物(insulin receptor substrate,IRS)在哮喘发病中也起很大作用,通过探索IRS如IRS-1、IRS-2和SHc(SHc是含有SH结构域的基因编码的蛋白产物),尤其是SHc在哮喘中的作用机制,将有望在哮喘治疗上提出新的治疗方向.
지기관효천(간칭효천)시유다충인소인기적질병,목전공인적발병궤제시기도염증가설.근래연구표명,이도소수체저물(insulin receptor substrate,IRS)재효천발병중야기흔대작용,통과탐색IRS여IRS-1、IRS-2화SHc(SHc시함유SH결구역적기인편마적단백산물),우기시SHc재효천중적작용궤제,장유망재효천치료상제출신적치료방향.
Bronchial asthma is a disease caused by a variety of factors,the currently accepted pathogenesis is mainly airway inflammation hypothesis.Recently,mangy reports have demonstrated that the insulin receptor substrate (IRS) also plays an important role in the pathogenesis of bronchial asthma,by exploring IRS,such as the IRS-1、IRS-2 and SHc,especially the SHc,in the action mechanism of bronchial asthma,is expected to propose a new therapeutic direction in bronchial asthma treatment.